E913

E913 is a CCR5 antagonist that competes with the binding of antibodies to CCR5 which recognize the C-terminal half of the second extracellular loop (ECL2B) of CCR5. E913 can specifically block the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 (IC₅₀ = 0.002 μM) and MIP-1alpha-elicited cellular Ca²⁺ mobilization (IC₅₀ = 0.02 μM). E913 inhibits the replication of laboratory and primary R5 HIV-1 strains as well as various multidrug-resistant monocyte/macrophage tropic (R5) HIV-1 (IC₅₀ = 0.03-0.06 μM). E913 can be used for the research of infection, such as HIV-1 infection.

• Data Sheet (268 KB)